Zheng Quan Shi Bao·2025-11-02 10:18Group 1: Company Announcements - Multiple A-share companies announced operational updates on November 2 [1] - Betta Pharmaceuticals (300558) entered a strategic partnership with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to obtain exclusive general agency rights for a recombinant coagulation factor product [4] - Betta Pharmaceuticals aims to enhance its new drug innovation technology platform and product pipeline through this collaboration, providing support in R&D, clinical trials, production, registration, and sales promotion [4] Group 2: Product Details - Betta Pharmaceuticals' exclusive general agency rights include the recombinant human coagulation factor VIII-Fc fusion protein (FRSW117), which has completed Phase III clinical trials and is intended for patients with Hemophilia A [4] - FRSW117 is classified as a Class 1 therapeutic biological product, with a dosing frequency of once a week for preventive treatment [4] - Currently, no domestic long-acting recombinant factor VIII products have been approved for market release in China [4] Group 3: Financial Contracts - Lanjian Intelligent (688557) signed a significant daily operational contract worth 138 million yuan [5][7] - The contract with Nine Technology (Zhuhai) Co., Ltd. is expected to positively impact the company's performance in 2026 [7] - ST Yifei (688646) announced an overseas procurement order valued at approximately 190 million yuan, accounting for 27.46% of the company's audited revenue for 2024 [8][10]